SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Grönhagen Siska Carola)
 

Sökning: WFRF:(Grönhagen Siska Carola) > (2004) > Effect of fluvastat...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003917naa a2200565 4500
001oai:DiVA.org:uu-105019
003SwePub
008090531s2004 | |||||||||||000 ||eng|
009oai:DiVA.org:liu-48286
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1050192 URI
0247 a https://doi.org/10.1111/j.1523-1755.2004.00919.x2 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-482862 URI
040 a (SwePub)uud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Fellström, Bengtu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)bengfell
2451 0a Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
264 1b Elsevier BV,c 2004
338 a print2 rdacarrier
520 a BACKGROUND: Hyperlipidemia is a risk factor for long-term renal transplant dysfunction, but no prospective clinical trials have investigated the effects of statin treatment on graft function in renal transplant recipients. The aim of the present study was to evaluate the effect of fluvastatin on long-term renal transplant function and development of chronic allograft nephropathy in the ALERT (Assessment of Lescol in Renal Transplantation) study. METHODS: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40 mg and 80 mg daily, in renal transplant recipients. Patients were randomized to receive either fluvastatin (N= 1050) or placebo (N= 1052) and followed for five to six years. Renal end points included graft loss or doubling of serum creatinine or death; glomerular filtration rate (GFR) was also measured during follow-up in a subset of patients (N= 439). RESULTS: There were 283 patients (13.5%) with graft loss, mainly due to chronic rejection (82%), yielding an annual rate of 2.4%. Fluvastatin treatment significantly lowered mean low-density lipoprotein (LDL)-cholesterol levels by 32% (95% CI -33 to -30) compared with placebo, but had no significant effect on the incidence of renal graft loss or doubling of serum creatinine, or decline in GFR throughout follow-up in the whole study population. Neither was any treatment effect by fluvastatin found in any of the subgroups analyzed. CONCLUSION: Fluvastatin treatment significantly improves lipid values in renal transplant recipients but has no effect on graft loss or doubling of serum creatinine.
653 a lipoprotein
653 a renal
653 a transplantation
653 a HMG-CoA reductase inhibitor
653 a chronic rejection
653 a MEDICINE
653 a MEDICIN
7001 a Holdaas, Hallvard4 aut
7001 a Jardine, Alan G.4 aut
7001 a Holme, Ingar4 aut
7001 a Nyberg, Gudrun4 aut
7001 a Fauchald, Per4 aut
7001 a Grönhagen-Siska, Carola4 aut
7001 a Madsen, Sören4 aut
7001 a Neumayer, Hans-Hellmut4 aut
7001 a Cole, Edward4 aut
7001 a Maes, Bart4 aut
7001 a Ambühl, Patrice4 aut
7001 a Olsson, Andersu Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US4 aut0 (Swepub:liu)andol21
7001 a Hartmann, Anders4 aut
7001 a Logan, John O.4 aut
7001 a Pedersen, Terje R.4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Kidney Internationald : Elsevier BVg 66:4, s. 1549-1555q 66:4<1549-1555x 0085-2538x 1523-1755
8564 u http://www.kidney-international.org/article/S008525381550224X/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-105019
8564 8u https://doi.org/10.1111/j.1523-1755.2004.00919.x
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-48286

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy